Bausch + Lomb screens attractively valued at a forward P/E of 13.9x with a PEG of 0.05, and generates positive free cash flow despite reporting a GAAP loss — a signal that economic earnings are stronger than reported income. The primary near-term risks are declining volume momentum and a 57% revenue concentration in the Vision Care segment.
Thesis pillars
- Fcf Positive Despite Gaap Loss→Stable
- Near Zero Peg Deep Value→Stable
- Declining Volume Momentum Overhang→Stable
- +1 more pillar — see the Why tab for full reasoning
Bausch + Lomb Corporation (BLCO) Stock Analysis
Healthcare · Medical Instruments & Supplies
Hold if already holding. Not a fresh buy at $17.11, but acceptable to hold if already in. Reasons: Concentration risk — Product: Vision Care segment (57.0%); Concentration risk — Supplier: single source or limited number of sources.
Bausch + Lomb makes contact lenses, ophthalmic pharmaceuticals, surgical equipment, and consumer eye care products across three segments — Vision Care (57% of 2025 revenue), Pharmaceuticals (25%), and Surgical (18%) — with a presence in roughly 100 countries. The company... Read more
Hold if already holding. Not a fresh buy at $17.11, but acceptable to hold if already in. Reasons: Concentration risk — Product: Vision Care segment (57.0%); Concentration risk — Supplier: single source or limited number of sources. Chart setup: No clear chart pattern; technical signals are mixed. Downgraded from BUY WAIT — price $17.11 has reached target $16.91. No upside to wait for. Score 5.5/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.50, earnings proximity 23d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-07-07Recent Developments — Bausch + Lomb Corporation
Latest news
- NEWS Bausch + Lomb Corporation 2026 Q1 - Results - Earnings Call Presentation (NYSE:BLCO) 2026-04-29 - Seeking Alpha — Seeking Alpha neutral
- NEWS Bausch + Lomb (BLCO) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance — Yahoo Finance positive
- NEWS Bausch + Lomb (NYSE:BLCO) Posts Better-Than-Expected Sales In Q1 CY2026 - StockStory — StockStory positive
- NEWS Bausch + Lomb (NYSE:BLCO) Posts Better-Than-Expected Sales In Q1 CY2026 - TradingView — TradingView positive
- NEWS Is It Time To Reconsider Bausch + Lomb (BLCO) After Its 28% One-Year Rally? - Yahoo Finance — Yahoo Finance positive
Generated 2026-07-07T13:52:21Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductVision Care segment57%10-K Item 1: 'Vision Care | | $ | 2,923 | | | 57 | % ... Total revenues | | $ | 5,101 | | | 100 | %'
- HIGHSuppliersingle source or limited number of sources10-K Item 1A: 'Certain of our products or components thereof are available from a single source or a limited number of sources'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $17.11, but acceptable to hold if already in. Reasons: Concentration risk — Product: Vision Care segment (57.0%); Concentration risk — Supplier: single source or limited number of sources. Chart setup: No clear chart pattern; technical signals are mixed. Downgraded from BUY WAIT — price $17.11 has reached target $16.91. No upside to wait for. Target $16.91 (-1.2%), stop $14.21 (−20.4%), A.R:R -0.6:1. Score 5.5/10, moderate confidence.
Take-profit target: $16.91 (+13.6% upside). Target $16.91 (-1.2%), stop $14.21 (−20.4%), A.R:R -0.6:1. Stop-loss: $14.21.
Concentration risk — Product: Vision Care segment (57.0%); Concentration risk — Supplier: single source or limited number of sources; Analyst target reached - limited upside remaining.
Bausch + Lomb Corporation trades at a P/E of N/A (forward 16.0). TrendMatrix value score: 6.8/10. Verdict: Hold.
18 analysts cover BLCO with a consensus score of 3.6/5. Average price target: $18.
What does Bausch + Lomb Corporation do?Bausch + Lomb makes contact lenses, ophthalmic pharmaceuticals, surgical equipment, and consumer eye care products...
Bausch + Lomb makes contact lenses, ophthalmic pharmaceuticals, surgical equipment, and consumer eye care products across three segments — Vision Care (57% of 2025 revenue), Pharmaceuticals (25%), and Surgical (18%) — with a presence in roughly 100 countries. The company generated $5.1 billion in total revenues in 2025 across approximately 13,000 employees globally.